REFERENCES
1. Natale P, Palmer SC, Saglimbene VM, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2022;2:CD008834.
2. Jain N, Martin BC, Dai J, et al. Age modifies intracranial and gastrointestinal bleeding risk from P2Y12 inhibitors in patients receiving dialysis. Kidney360 2022;3:1374-83.
3. Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45:16-153.
4. Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:105-10.
5. Claudio P, Gabriella M. Nephrotic syndrome: pathophysiology and consequences. J Nephrol 2023;36:2179-90.
6. Gritters M, Borgdorff P, Grooteman MP, et al. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility? Nephrol Dial Transplant 2008;23:2911-7.
7. Martin JF, D’Avino PP. A theory of rapid evolutionary change explaining the de novo appearance of megakaryocytes and platelets in mammals. J Cell Sci 2022;135:jcs260286.
8. Trowbridge EA, Harley PJ. A computer model of the random binary sequential division of megakaryocyte cytoplasm to produce platelets. Phys Med Biol 1984;29:1477-87.
9. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013;98:10-23.
10. Dowling MR, Josefsson EC, Henley KJ, Hodgkin PD, Kile BT. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood 2010;116:1776-8.
11. Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br J Haematol 1969;17:225-9.
12. Hancock V, Martin JF, Lelchuk R. The relationship between human megakaryocyte nuclear DNA content and gene expression. Br J Haematol 1993;85:692-7.
13. Martin JF, Kristensen SD, Mathur A, Grove EL, Choudry FA. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol 2012;9:658-70.
14. Debili N, Masse JM, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood 1993;82:84-95.
15. Hacein-Bey-Abina S, Estienne M, Bessoles S, et al. Erythropoietin is a major regulator of thrombopoiesis in thrombopoietin-dependent and -independent contexts. Exp Hematol 2020;88:15-27.
16. Nishimura S, Nagasaki M, Kunishima S, et al. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol 2015;209:453-66.
17. Hasegawa T, Koiwa F, Akizawa T. Anemia in conventional hemodialysis: finding the optimal treatment balance. Semin Dial 2018;31:599-606.
18. Anding K, Gross P, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant 2003;18:2067-73.
19. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008;3:1526-33.
20. Lisowska KA, Storoniak H, Dębska-Ślizień A. T cell subpopulations and cytokine levels in hemodialysis patients. Hum Immunol 2022;83:134-43.
21. van Bladel ER, de Jager RL, Walter D, et al. Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro. BMC Nephrol 2012;13:127.
23. Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial 2009;22:279-86.
24. Baaten CCFMJ, Sternkopf M, Henning T, Marx N, Jankowski J, Noels H. Platelet function in CKD: a systematic review and meta-analysis. J Am Soc Nephrol 2021;32:1583-98.
25. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr 2012;22:149-56.
26. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007;3:138-53.
27. Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int 2012;82:147-57.
28. Aggarwal A, Kabbani SS, Rimmer JM, et al. Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. Am J Kidney Dis 2002;40:315-22.
29. Gawaz MP, Mujais SK, Schmidt B, Gurland HJ. Platelet-leukocyte aggregation during hemodialysis. Kidney Int 1994;46:489-95.
30. Ashman N, Macey MG, Fan SL, Azam U, Yaqoob MM. Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients. Nephrol Dial Transplant 2003;18:2088-96.
31. Schoorl M, Schoorl M, Nubé MJ, Bartels PC. Platelet depletion, platelet activation and coagulation during treatment with hemodialysis. Scand J Clin Lab Invest 2011;71:240-7.
32. Schoorl M, Schoorl M, Bartels PC. Changes in platelet volume, morphology and RNA content in subjects treated with haemodialysis. Scand J Clin Lab Invest 2008;68:335-42.
33. Schoorl M, Bartels PC, Gritters M, Fluitsma D, Musters R, Nubé MJ. Electron microscopic observation in case of platelet activation in a chronic haemodialysis subject. Hematol Rep 2011;3:e15.
34. Schoorl M, Grooteman MP, Bartels PC, Nubé MJ. Aspects of platelet disturbances in haemodialysis patients. Clin Kidney J 2013;6:266-71.
35. Sloos PH, Vulliamy P, van't Veer C, et al. Platelet dysfunction after trauma: from mechanisms to targeted treatment. Transfusion 2022;62 Suppl 1:S281-300.
36. Jurk K, Jahn UR, Van Aken H, et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004;91:334-44.
37. Riedl J, Kaider A, Marosi C, et al. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. Thromb Haemost 2017;117:90-8.
38. Dewanjee MK, Kapadvanjwala M, Cavagnaro CF, et al. In vitro and in vivo evaluation of the comparative thrombogenicity of cellulose acetate hemodialyzers with radiolabeled platelets. ASAIO J 1994;40:49-55.
39. Popescu NI, Lupu C, Lupu F. Disseminated intravascular coagulation and its immune mechanisms. Blood 2022;139:1973-86.
40. Arepally GM, Padmanabhan A. Heparin-induced thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol 2021;41:141-52.
42. Martin JF, Daniel TD, Trowbridge EA. Acute and chronic changes in platelet volume and count after cardiopulmonary bypass induced thrombocytopenia in man. Thromb Haemost 1987;57:55-8.
43. Kim S, Molnar MZ, Fonarow GC, et al. Mean platelet volume and mortality risk in a national incident hemodialysis cohort. Int J Cardiol 2016;220:862-70.
44. Cho A, Choi MJ, Lee YK, et al. Effects of aspirin resistance and mean platelet volume on vascular access failure in hemodialysis patients. Korean J Intern Med 2019;34:1304-12.
45. International Atomic Energy Agency. Radiolabelled autologous cells: methods and standardization for clinical use. Vienna: International Atomic Energy Agency; 2015. Available from: https://www-pub.iaea.org/MTCD/Publications/PDF/Pub1437web-26591607.pdf [Last accessed on 1 June 2023].
46. Araújo NC, Suassuna JHR. The spleen size in patients undergoing hemodialysis. J Bras Nefrol 2021;43:61-7.
47. Hakim RM, Schafer AI. Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 1985;78:575-80.
48. Linthorst GE, Folman CC, van Olden RW, von dem Borne AE. Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J 2002;3:38-42.
49. Ando M, Iwamoto Y, Suda A, Tsuchiya K, Nihei H. New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels. Blood 2001;97:915-21.
50. Mahlknecht U, Kaiser S. Age-related changes in peripheral blood counts in humans. Exp Ther Med 2010;1:1019-25.
51. Toyoda Y, Tateno K, Takeda Y, Kobayashi Y. Significance of mild thrombocytopenia in maintenance hemodialysis patients; a retrospective cohort study. Platelets 2022;33:735-42.
52. Panova-Noeva M, Wagner B, Nagler M, et al. Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observation studies. EBioMedicine 2020;60:102978.
53. Zimmermann N, Kurt M, Wenk A, Winter J, Gams E, Hohlfeld T. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Eur J Cardiothorac Surg 2005;27:606-10.
54. Gäckler A, Rohn H, Lisman T, et al. Evaluation of hemostasis in patients with end-stage renal disease. PLoS One 2019;14:e0212237.
55. Mitic BP, Dimitrijevic ZM, Hosokawa K, et al. Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system. Int Urol Nephrol 2022;54:2695-702.
56. Jain N, Corken AL, Kumar A, Davis CL, Ware J, Arthur JM. Role of platelets in chronic kidney disease. J Am Soc Nephrol 2021;32:1551-8.
57. Chuang YC, Chen JB, Yang LC, Kuo CY. Significance of platelet activation in vascular access survival of haemodialysis patients. Nephrol Dial Transplant 2003;18:947-54.
58. Eknoyan G, Wacksman SJ, Glueck HI, Will JJ. Platelet function in renal failure. N Engl J Med 1969;280:677-81.
59. Parguiña AF, Grigorian-Shamajian L, Agra RM, et al. Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One 2010;5:e13404.
60. López-Farré AJ, Zamorano-Leon JJ, Azcona L, et al. Proteomic changes related to “bewildered” circulating platelets in the acute coronary syndrome. Proteomics 2011;11:3335-48.
61. Goudswaard LJ, Williams CM, Khalil J, et al. Alterations in platelet proteome signature and impaired platelet integrin αIIbβ3 activation in patients with COVID-19. J Thromb Haemost 2023;21:1307-21.
62. Trugilho MRO, Azevedo-Quintanilha IG, Gesto JSM, et al. Platelet proteome reveals features of cell death, antiviral response and viral replication in covid-19. Cell Death Discov 2022;8:324.
63. Tateno K, Toyoda Y, Hirose M, Kondo N, Kanda M, Kobayashi Y. Abstract 11022: progressive thrombocytopenia in critical limb ischemia as a novel cardiovascular rsk. Circulation 2019;140:A11022.
64. Benlachgar N, Doghmi K, Masrar A, Mahtat EM, Harmouche H, Tazi Mezalek Z. Immature platelets: a review of the available evidence. Thromb Res 2020;195:43-50.
65. Himmelfarb J, Holbrook D, McMonagle E, Ault K. Increased reticulated platelets in dialysis patients. Kidney Int 1997;51:834-9.
66. Tàssies D, Reverter JC, Cases A, et al. Reticulated platelets in uremic patients: effect of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Hematol 1995;50:161-6.
67. Tàssies D, Reverter JC, Cases A, Calls J, Escolar G, Ordinas A. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: association with early improvement in platelet function. Am J Hematol 1998;59:105-9.
68. Baaten CCFMJ, Ten Cate H, van der Meijden PEJ, Heemskerk JWM. Platelet populations and priming in hematological diseases. Blood Rev 2017;31:389-99.
69. Gafter U, Bessler H, Malachi T, Zevin D, Djaldetti M, Levi J. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron 1987;45:207-10.
70. Levine RF, Eldor A, Shoff PK, Kirwin S, Tenza D, Cramer EM. Circulating megakaryocytes: delivery of large numbers of intact, mature megakaryocytes to the lungs. Eur J Haematol 1993;51:233-46.
71. Davis RE, Stenberg PE, Levin J, Beckstead JH. Localization of megakaryocytes in normal mice and following administration of platelet antiserum, 5-fluorouracil, or radiostrontium: evidence for the site of platelet production. Exp Hematol 1997;25:638-48.
72. Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. Am J Pathol 2000;157:69-74.
74. Aabo K, Hansen KB. Megakaryocytes in pulmonary blood vessels. I. Incidence at autopsy, clinicopathological relations especially to disseminated intravascular coagulation. Acta Pathol Microbiol Scand A 1978;86:285-91.
75. Pedersen NT. Occurrence of megakaryocytes in various vessels and their retention in the pulmonary capillaries in man. Scand J Haematol 1978;21:369-75.
76. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 2017;544:105-9.
77. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-5.
78. Weng CH, Lu KY, Hu CC, Huang WH, Wang IK, Yen TH. Bone marrow pathology predicts mortality in chronic hemodialysis patients. Biomed Res Int 2015;2015:160382.
79. Yilmaz M, Karakuş V, Kaya E, İlhanlı N, Huddam B. Evaluation of bone marrow findings in hemodialysis patients with erythropoietin-resistant anemia. Ther Apher Dial 2024;28:218-24.
80. Pariser DN, Hilt ZT, Ture SK, et al. Lung megakaryocytes are immune modulatory cells. J Clin Invest 2021;131:137377.
81. Yeung AK, Villacorta-Martin C, Hon S, Rock JR, Murphy GJ. Lung megakaryocytes display distinct transcriptional and phenotypic properties. Blood Adv 2020;4:6204-17.
82. Qiu J, Ma J, Dong Z, et al. Lung megakaryocytes engulf inhaled airborne particles to promote intrapulmonary inflammation and extrapulmonary distribution. Nat Commun 2024;15:7396.
83. Gelon L, Fromont L, Lefrançais E. Occurrence and role of lung megakaryocytes in infection and inflammation. Front Immunol 2022;13:1029223.
84. Gritters M, Grooteman MP, Schoorl M, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006;21:153-9.
85. Liakopoulos V, Roumeliotis S, Zarogiannis S, Eleftheriadis T, Mertens PR. Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial 2019;32:58-71.
86. Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM. Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. J Am Soc Nephrol 1993;4:178-86.
87. Meyring-Wösten A, Kuntsevich V, Campos I, et al. Erythrocyte sodium sensitivity and eryptosis in chronic hemodialysis patients. Kidney Blood Press Res 2017;42:314-26.
88. Pernow J, Mahdi A, Yang J, Zhou Z. Red blood cell dysfunction: a new player in cardiovascular disease. Cardiovasc Res 2019;115:1596-605.
89. Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR. Oxidative stress in hemodialysis patients: a review of the literature. Oxid Med Cell Longev 2017;2017:3081856.
90. Arthur JF, Jandeleit-Dahm K, Andrews RK. Platelet hyperreactivity in diabetes: focus on GPVI signaling-are useful drugs already available? Diabetes 2017;66:7-13.
91. Chatterjee M, Rath D, Schlotterbeck J, et al. Regulation of oxidized platelet lipidome: implications for coronary artery disease. Eur Heart J 2017;38:1993-2005.
92. Melk A, Halloran PF. Cell senescence and its implications for nephrology. J Am Soc Nephrol 2001;12:385-93.
93. Carracedo J, Alique M, Vida C, et al. Mechanisms of cardiovascular disorders in patients with chronic kidney disease: a process related to accelerated senescence. Front Cell Dev Biol 2020;8:185.
94. Stenvinkel P, Diczfalusy U, Lindholm B, Heimbürger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant 2004;19:972-6.
95. Di Micco R, Krizhanovsky V, Baker D, d’Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol 2021;22:75-95.
96. Zhang L, Pitcher LE, Yousefzadeh MJ, Niedernhofer LJ, Robbins PD, Zhu Y. Cellular senescence: a key therapeutic target in aging and diseases. J Clin Invest 2022;132:e158450.
97. Ramírez R, Carracedo J, Soriano S, et al. Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis. Am J Kidney Dis 2005;45:353-9.
98. Hirashio S, Nakashima A, Doi S, et al. Telomeric g-tail length and hospitalization for cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 2014;9:2117-22.
100. Ong SM, Hadadi E, Dang TM, et al. The pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescence. Cell Death Dis 2018;9:266.
102. Davizon-Castillo P, McMahon B, Aguila S, et al. TNF-α-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood 2019;134:727-40.
103. Yamamoto T, Isaka Y. Pathological mechanisms of kidney disease in ageing. Nat Rev Nephrol 2024;20:603-15.
104. Besancenot R, Chaligné R, Tonetti C, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol 2010;8:e1000476.
105. Thongon N, Ma F, Santoni A, et al. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun 2021;12:6850.
106. Gekas C, Graf T. CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age. Blood 2013;121:4463-72.
107. Sanjuan-Pla A, Macaulay IC, Jensen CT, et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature 2013;502:232-6.
108. Pang WW, Price EA, Sahoo D, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA 2011;108:20012-7.
109. Choudry FA, Frontini M. Epigenetic control of haematopoietic stem cell aging and its clinical implications. Stem Cells Int 2016;2016:5797521.
110. Carrelha J, Mazzi S, Winroth A, et al. Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells. Nat Immunol 2024;25:1007-19.
111. Poscablo DM, Worthington AK, Smith-Berdan S, et al. An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis. Cell 2024;187:3090-107.e21.
112. Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J 1985;290:428-32.
113. Simon LM, Edelstein LC, Nagalla S, et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 2014;123:e37-45.
114. Campbell RA, Franks Z, Bhatnagar A, et al. Granzyme A in human platelets regulates the synthesis of proinflammatory cytokines by monocytes in aging. J Immunol 2018;200:295-304.
115. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-98.
116. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371:2477-87.
117. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017;377:111-21.
118. Sano S, Wang Y, Walsh K. Clonal hematopoiesis and its impact on cardiovascular disease. Circ J 2018;83:2-11.
119. Vlasschaert C, McNaughton AJM, Chong M, et al. Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol 2022;33:985-95.
120. Veninga A, De Simone I, Heemskerk JWM, Cate HT, van der Meijden PEJ. Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica 2020;105:2020-31.
121. Kristiansen MH, Kjær L, Skov V, et al. JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study. Blood Adv 2023;7:5825-34.
122. Hinckley J, Di Paola J. Genetic basis of congenital platelet disorders. Hematol Am Soc Hematol Educ Program 2014;2014:337-42.
123. Caiado F, Pietras EM, Manz MG. Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. J Exp Med 2021;218:e20201541.
124. Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood 2017;130:1693-8.
125. Sezaki M, Hayashi Y, Wang Y, Johansson A, Umemoto T, Takizawa H. Immuno-modulation of hematopoietic stem and progenitor cells in inflammation. Front Immunol 2020;11:585367.
126. Bochenek ML, Schütz E, Schäfer K. Endothelial cell senescence and thrombosis: ageing clots. Thromb Res 2016;147:36-45.
127. Sasaki K, Shoji T, Kabata D, et al. Oxidative stress and inflammation as predictors of mortality and cardiovascular events in hemodialysis patients: the DREAM cohort. J Atheroscler Thromb 2021;28:249-60.
128. Cianciolo G, Stefoni S, Donati G, et al. Intra- and post-dialytic platelet activation and PDGF-AB release: cellulose diacetate vs polysulfone membranes. Nephrol Dial Transplant 2001;16:1222-9.
129. Kessler M, Moureau F, Nguyen P. Anticoagulation in chronic hemodialysis: progress toward an optimal approach. Semin Dial 2015;28:474-89.
130. Ponchia PI, Ahmed R, Farag M, Alkhalil M. Antiplatelet therapy in end-stage renal disease patients on maintenance dialysis: a state-of-the-art review. Cardiovasc Drugs Ther 2023;37:975-87.
131. Mitchell E, Spencer Chapman M, Williams N, et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature 2022;606:343-50.
132. Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res 2018;122:337-51.
133. Molnar MZ, Streja E, Kovesdy CP, et al. High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. Am J Clin Nutr 2011;94:945-54.
134. Blair TA, Michelson AD, Frelinger AL 3rd. Mass cytometry reveals distinct platelet subtypes in healthy subjects and novel alterations in surface glycoproteins in glanzmann thrombasthenia. Sci Rep 2018;8:10300.
135. David Amir EA, Davis KL, Tadmor MD, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 2013;31:545-52.
